Dr Delia D’Avola undertook her medical training in Rome at Universidad Campus Bio-Medico, where she also completed her postgraduate training in Internal Medicine in 2008. With a specific interest in liver disease, she started her PhD in 2008 at the Universidad de Navarra, Spain, working on liver cancer and radioembolisation. Since then, she has worked as a hepatologist in the liver unit of Clinica Universidad de Navarra, attending patients with liver cancer and chronic liver diseases, including liver transplant patients. In 2017, she completed her postdoctoral training in the Liver Disease Department of Icahn School of Medicine at Mount Sinai Hospital, New York, working on liquid biopsy in liver cancer. She is currently a consultant hepatologist in the new premises of Clinica Universidad de Navarra in Madrid. As a translational researcher, Dr D’Avola has been working in Phase I and Phase I¬–II clinical trials of gene and cell therapy for the treatment of liver diseases, including metabolic disorders, liver cirrhosis and chronic hepatitis, and trials for the treatment of liver cancer with different agents, including radioembolisation, immunotherapy and targeted therapies. She was coordinator of the first-in-human Phase I–II clinical trial of gene therapy for acute intermittent porphyria and later principal investigator at an ENVISION clinical trial (NCT03338816) site for the treatment of acute porphyria. Since 2017, she has coordinated the porphyria unit at her hospital, predominantly focused on acute porphyrias. At national level, Dr D’Avola has been national coordinator of the Spanish group for the study of porphyrias (GEEP) since 2019 and is Assistant Professor at the Faculty of Medicine at Universidad de Navarra.